Visions - Summer 2009 - 8
(continued) Aside from the medical miracle it could provide, the financial burden on patients and their families could also be lessened, since the current medical cost of kidney dialysis per patient in the U.S. averages at $70,000 a year, with total cost in to U.S. patients of more than $30 billion a year. itself; Reata could be helped by bringing in a licensing partner. The Life Science Unit soon proceeded to secure meetings with Reata and seven Japanese pharmaceutical companies concerning distribution, with the meetings generating positive results. In his function as a facilitator,VP of Business Investment for SCOA and Director of Oxford Finance John Degen sees his engagement with Reata as a opportunity for SCOA to leverage the intellectual capital that Oxford has accumulated, and then offer new services to Oxford's customer base that are truly strategic in nature for all involved. “For Sumitomo as a whole, our initiative is to create new lines of business and incremental revenue for our Life Sciences business,” Degen said.“And at the same time, Reata has leveraged its borrowing relationship with Oxford for two additional key services: as a strategic partnering advisor for the Japanese market, and to act as a procurement and supply chain consultant in support of its drug manufacturing and development activities. Under this supply chain management, Reata can save millions of dollars in annual costs after RTA-402 goes into the market. I believe our efforts here will serve as a catalyst for other areas of the company to look within to create new revenue opportunities.” In the initial trials, RTA-402 has not only improved renal functions considerably, but could possibly reverse chronic kidney damage, giving it the potential to become a breakout treatment in this fight and a lifesaver for thousands of patients on dialysis and in need of liver transplants.Aside from the medical miracle it could provide, the financial burden on patients and their families could also be lessened, since the current medical cost of kidney dialysis per patient in the U.S. averages at $70,000 a year, with total cost in to U.S. patients of more than $30 billion a year. Reata will commence a larger clinical trial of RTA-402 soon, and if this trial goes well and the U.S. Food and Drug Administration grants approval, doctors could be administering the drug to CKD patients as early as 2012. For more information, please contact Yasunori Ishibashi at yasunori.ishibashi@sumitomocorp.com 8 visions Summer 2009
Visions - Summer 2009
Table of Contents for the Digital Edition of Visions - Summer 2009
Contents
Visions - Summer 2009
The Power of Wind Meets The Power of Business
The Space Age Metal With Mettle
SCOA Synergy Helps Fight Kidney Disease on Two Fronts
Man's Best Friend Gets Relief From New Flea Product
The View From Washington
Visions - Summer 2009 - Visions - Summer 2009
Visions - Summer 2009 - 2
Visions - Summer 2009 - The Power of Wind Meets The Power of Business
Visions - Summer 2009 - 4
Visions - Summer 2009 - The Space Age Metal With Mettle
Visions - Summer 2009 - 6
Visions - Summer 2009 - SCOA Synergy Helps Fight Kidney Disease on Two Fronts
Visions - Summer 2009 - 8
Visions - Summer 2009 - Man's Best Friend Gets Relief From New Flea Product
Visions - Summer 2009 - 10
Visions - Summer 2009 - The View From Washington
Visions - Summer 2009 - 12
https://www.nxtbook.com/nxtbooks/sumitomo/visions-spring2020
https://www.nxtbook.com/nxtbooks/sumitomo/visions-winter2020
https://www.nxtbook.com/nxtbooks/sumitomo/visions-fall2019
https://www.nxtbook.com/nxtbooks/sumitomo/visions-summer2019
https://www.nxtbook.com/nxtbooks/sumitomo/visions-spring2019
https://www.nxtbook.com/nxtbooks/sumitomo/visions-fallwinter2019
https://www.nxtbook.com/nxtbooks/sumitomo/visions-summer2018
https://www.nxtbook.com/nxtbooks/sumitomo/visions-winterspring2018
https://www.nxtbook.com/nxtbooks/sumitomo/visions-fall2017
https://www.nxtbook.com/nxtbooks/sumitomo/visions-summer2017
https://www.nxtbook.com/nxtbooks/sumitomo/visions-winterspring2017
https://www.nxtbook.com/nxtbooks/sumitomo/visions-fall16
https://www.nxtbook.com/nxtbooks/sumitomo/visions-springsummer16
https://www.nxtbook.com/nxtbooks/sumitomo/visions-winter16
https://www.nxtbook.com/nxtbooks/sumitomo/visions-fall15
https://www.nxtbook.com/nxtbooks/sumitomo/visions-summer15
https://www.nxtbook.com/nxtbooks/sumitomo/visions-spring15
https://www.nxtbook.com/nxtbooks/sumitomo/visions-winter15
https://www.nxtbook.com/nxtbooks/sumitomo/visions-summerfall14
https://www.nxtbook.com/nxtbooks/sumitomo/visions-summer14
https://www.nxtbook.com/nxtbooks/sumitomo/globalsolutions2014
https://www.nxtbook.com/nxtbooks/sumitomo/visions-winter14
https://www.nxtbook.com/nxtbooks/sumitomo/visions-fall13
https://www.nxtbook.com/nxtbooks/sumitomo/visions-springsummer13
https://www.nxtbook.com/nxtbooks/sumitomo/visions-winter13
https://www.nxtbook.com/nxtbooks/sumitomo/visions-fall12
https://www.nxtbook.com/nxtbooks/sumitomo/visions-springsummer12
https://www.nxtbook.com/nxtbooks/sumitomo/visions-winter12
https://www.nxtbook.com/nxtbooks/sumitomo/visions-fall11
https://www.nxtbook.com/nxtbooks/sumitomo/visions-summer11
https://www.nxtbook.com/nxtbooks/sumitomo/visions-spring11
https://www.nxtbook.com/nxtbooks/sumitomo/visions-winter11
https://www.nxtbook.com/nxtbooks/sumitomo/visions-fall10
https://www.nxtbook.com/nxtbooks/sumitomo/visions-summer10
https://www.nxtbook.com/nxtbooks/sumitomo/visions-winterspring10
https://www.nxtbook.com/nxtbooks/sumitomo/visions-fall09
https://www.nxtbook.com/nxtbooks/sumitomo/visions-summer09
https://www.nxtbook.com/nxtbooks/sumitomo/visions-spring09
https://www.nxtbook.com/nxtbooks/sumitomo/visions-winter09
https://www.nxtbook.com/nxtbooks/sumitomo/visions-fall08
https://www.nxtbook.com/nxtbooks/sumitomo/visions-spring08
https://www.nxtbook.com/nxtbooks/sumitomo/visions-winter08
https://www.nxtbook.com/nxtbooks/sumitomo/visions-fall07
https://www.nxtbook.com/nxtbooks/sumitomo/vision-summer07
https://www.nxtbookmedia.com